Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Cimini, Eleonora ^a   Bonnafous, Cécile ^b   Bordoni, Veronica ^a   Lalle, Eleonora ^a   Sicard, Helene ^b   Sacchi, Alessandra ^a   Berno, Giulia ^a   Gioia, Cristiana ^a   D'Offizi, Gianpiero ^a   Visco Comandini, Ubaldo ^a   Vlassi, Chrysoula ^a   Capobianchi, Maria Rosaria ^a   Martini, Federico ^a   Agrati, Chiara ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b INNATE PHARMA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GAMMA INTERFERON; MESSENGER RNA; PEGINTERFERON ALPHA2A;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GAMMA DELTA T LYMPHOCYTE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE FUNCTION; MACACA FASCICULARIS; MALE; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; RNA STABILITY; RNA TRANSCRIPTION; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANIMALS; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS C VIRUS; MACACA FASCICULARIS; PRIMATES;

EID: 84861319784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037014     Document Type: Article

References (46)

1. WHO, (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
3. Sarrazin C, Zeuzem S, (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
4. Hayashi N, Takehara T, (2006) Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 41: 17-27.
5. De FR, Migliaccio G, (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436: 953-960 doi:10.1038/nature04080.
6. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, et al. (2006) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131: 997-1002 doi:10.1053/j.gastro.2006.07.013.
7. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, (2005) T cell response in hepatitis C virus infection. J Clin Virol 32: 75-85.
8. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, et al. (2010) Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138: 325-335 doi:10.1053/j.gastro.2009.08.066.
9. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, et al. (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137: 1151-60, 1160 doi:10.1053/j.gastro.2009.05.047.
10. Par G, Rukavina D, Podack ER, Horanyi M, Szekeres-Bartho J, et al. (2002) Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J Hepatol 37: 514-522.
11. Gougeon ML, Malkovsky M, Casetti R, Agrati C, Poccia F, (2002) Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? Vaccine 20: 1938-1941.
12. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, et al. (2009) Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS 23: 555-565.
13. Poccia F, Agrati C, Martini F, Capobianchi MR, Wallace M, et al. (2005) Antiviral reactivities of gammadelta T cells. Microbes Infect 7: 518-528.
14. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, et al. (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155-158.
15. Kunzmann V, Bauer E, Wilhelm M, (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340: 737-738.
16. Qin G, Mao H, Zheng J, Sia SF, Liu Y, et al. (2009) Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis 200: 858-865.
17. Conti L, Casetti R, Cardone M, Varano B, Martino A, et al. (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174: 252-260.
18. Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, et al. (2009) Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 182: 522-529.
19. Poccia F, Agrati C, Martini F, Mejia G, Wallace M, et al. (2005) Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunol Lett 100: 14-20.
20. Martini F, Urso R, Gioia C, De Felici A, Narciso P, et al. (2000) gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology 100: 481-486.
21. Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, et al. (2006) Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. Int Immunol 18: 11-18.
22. Larkin J, Jin L, Farmen M, Venable D, Huang Y, et al. (2003) Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 23: 247-257.
23. Abbate I, Romano M, Longo R, Cappiello G, Lo IO, et al. (2003) Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. J Med Virol 70: 581-587.
24. Wiegand J, Cornberg M, Aslan N, Schlaphoff V, Sarrazin C, et al. (2007) Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther 12: 303-316.
25. Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, et al. (2006) Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis 193: 1244-1249.
26. Agrati C, Castilletti C, De Santis R, Cimini E, Bordi L, et al. (2006) Interferon-gamma-mediated antiviral immunity against orthopoxvirus infection is provided by gamma delta T cells. J Infect Dis 193: 1606-1607.
27. Poccia F, Battistini L, Cipriani B, Mancino G, Martini F, et al. (1999) Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis 180: 858-861.
28. Rodrigue-Gervais IG, Rigsby H, Jouan L, Sauve D, Sekaly RP, et al. (2010) Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 184: 3134-3144.
29. Kim PS, Ahmed R, (2010) Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22: 223-230.
30. Gan YH, Lui SS, Malkovsky M, (2001) Differential susceptibility of naive and activated human gammadelta T cells to activation-induced cell death by T-cell receptor cross-linking. Mol Med 7: 636-643.
31. Sacchi A, Tempestilli M, Turchi F, Agrati C, Casetti R, et al. (2009) CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients. J Infect Dis 199: 432-436.
32. Farag MM, Weigand K, Encke J, Momburg F, (2011) Activation of natural killer cells by hepatitis C virus particles in vitro. Clin Exp Immunol 165: 352-362 doi:10.1111/j.1365-2249.2011.04431.x.
33. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B, (2009) Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49: 12-21 doi:10.1002/hep.22624.
34. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, et al. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195: 35-41.
35. Tseng CT, Miskovsky E, Houghton M, Klimpel GR, (2001) Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 33: 1312-1320 doi:10.1053/jhep.2001.24269.
36. Kunzmann V, Kretzschmar E, Herrmann T, Wilhelm M, (2004) Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons. Immunology 112: 369-377.
37. Jia Y, Wei L, Jiang D, Wang J, Cong X, et al. (2007) Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8. J Gastroenterol Hepatol 22: 1278-1285.
38. Levy DE, Lew DJ, Decker T, Kessler DS, Darnell JE Jr, (1990) Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 9: 1105-1111.
39. Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, et al. (2005) Coordinate induction of IFN-alpha and-gamma by SARS-CoV also in the absence of virus replication. Virology 341: 163-169 doi:10.1016/j.virol.2005.07.015.
40. Mavropoulos A, Sully G, Cope AP, Clark AR, (2005) Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 105: 282-288.
41. Anderson P, (2010) Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol 10: 24-35.
42. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, et al. (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132: 1270-1278 doi:10.1053/j.gastro.2007.01.041.
43. Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, et al. (2005) In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175: 5471-5480.
44. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, et al. (2007) Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457.
45. Bonneville M, Scotet E, (2006) Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18: 539-546.
46. Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, et al. (1995) Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 3: 495-507.